Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Drug Metabolism and Personalized Therapy

Official journal of the European Society of Pharmacogenomics and Personalised Therapy

Editor-in-Chief: Llerena, Adrián

Editorial Board: Benjeddou, Mongi / Chen, Bing / Dahl, Marja-Liisa / Devinsky, Ferdinand / Hirata, Rosario / Hubacek, Jaroslav A. / Ingelman-Sundberg, Magnus / Maitland-van der Zee, Anke-Hilse / Manolopoulos, Vangelis G. / Marc, Janja / Melichar, Bohuslav / Meyer, Urs A. / Nair, Sujit / Nofziger, Charity / Peiro, Ana / Sadee, Wolfgang / Salazar, Luis A. / Simmaco, Maurizio / Turpeinen, Miia / Schaik, Ron / Shin, Jae-Gook / Visvikis-Siest, Sophie / Zanger, Ulrich M.


CiteScore 2018: 1.01

SCImago Journal Rank (SJR) 2018: 0.277
Source Normalized Impact per Paper (SNIP) 2018: 0.446

Online
ISSN
2363-8915
See all formats and pricing
More options …
Volume 34, Issue 2

Issues

Regulatory sciences and translational pharmacogenetics: amitriptyline as a case in point

Luana Mifsud Buhagiar
  • Corresponding author
  • Medicines Authority, Malta Life Sciences Park, San Ġwann, Malta
  • Department of Pharmacy, Faculty of Medicine and Surgery, University of Malta, Msida, Malta
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Benjamin Micallef / John Joseph Borg / Helen Vella / Anthony Serracino Inglott
  • Medicines Authority, Malta Life Sciences Park, San Ġwann, Malta
  • Department of Pharmacy, Faculty of Medicine and Surgery, University of Malta, Msida, Malta
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Godfrey LaFerla
Published Online: 2019-05-30 | DOI: https://doi.org/10.1515/dmpt-2019-0005

Abstract

Regulatory developments and clinical implementation, or the lack thereof, are primary clinchers, in the enduring endeavors to realize the translational quality of pharmacogenetics. Here, we present the case of amitriptyline, an established drug with pharmacogenetic implications. The integration of pharmacogenetic information in the official product literature and throughout the evaluation of safety concerns is considered. In our opinion, apart from emboldening genomic research in drug development and the valid pursuit towards global harmonization in the field, it is rational to look into the applicability of the data we have today.

Keywords: established drugs; labeling; pharmacogenetics; regulatory; vigilance

References

  • [1]

    International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 2004;431:931–45.PubMedGoogle Scholar

  • [2]

    Prasad K, Breckenridge A. Pharmacogenomics: a new clinical or regulatory paradigm? European experiences of pharmacogenomics in drug regulation and regulatory initiatives. Drug Discov Today 2011;16:867–72.CrossrefWeb of SciencePubMedGoogle Scholar

  • [3]

    Maliepaard M, Nofziger C, Papaluca M, Zineh I, Uyama Y, Prasad K, et al. Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective. Nat Rev Drug Discov 2013;12:103–15.CrossrefPubMedWeb of ScienceGoogle Scholar

  • [4]

    Ehmann F, Caneva L, Prasad K, Paulmichl M, Maliepaard M, Llerena A, et al. Pharmacogenomic information in drug labels: Eur Med Agency perspective. Pharmacogenomics J 2015;15:201–10.CrossrefGoogle Scholar

  • [5]

    Harper AR, Topol EJ. Pharmacogenomics in clinical practice and drug development. Nat Biotechnol 2012;30:1117–24.PubMedWeb of ScienceCrossrefGoogle Scholar

  • [6]

    Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2018;391:1357–66.Web of ScienceCrossrefPubMedGoogle Scholar

  • [7]

    De Grandis G, Halgunset V. Conceptual and terminological confusion around personalised medicine: a coping strategy. BMC Med Ethics 2016;17:43.PubMedCrossrefWeb of ScienceGoogle Scholar

  • [8]

    Sadée W, Dai Z. Pharmacogenetics/genomics and personalized medicine. Hum Mol Genet 2005;14:207–14.CrossrefGoogle Scholar

  • [9]

    Dove ES, Özdemir V. All the post-genomic world is a stage: the actors and narrators required for translating pharmacogenomics into public health. Per Med 2013;10:213–6.CrossrefPubMedGoogle Scholar

  • [10]

    Cheung KC, Nijenhuis M, Crommentuijn – van Rhenen M, Holsappel I. Evidence-based pharmacogenetic guidelines in the Netherlands. Presentation at the 2017 FIP Congress; May 2017; Stockholm (Sweden).Google Scholar

  • [11]

    Nassan M, Nicholson WT, Elliott MA, Rohrer Vitek CR, Black JL, Frye MA, et al. Pharmacokinetic pharmacogenetic prescribing guidelines for antidepressants: a template for psychiatric precision medicine. Mayo Clin Proc 2016;91:897–907.Web of SciencePubMedCrossrefGoogle Scholar

  • [12]

    Borg JJ, Tanti A, Kouvelas D, Lungu C, Pirozynski M, Serracino-Inglott A, Aislaitner G. European Union pharmacovigilance capabilities: potential for the new legislation. Ther Adv Drug Saf 2015;6:120–40.Web of ScienceCrossrefPubMedGoogle Scholar

  • [13]

    European Medicines Agency. Guideline on key aspects for the use of pharmacogenomics in the pharmacovigilance of medicinalproducts. EMA/CHMP/281371/2013.EMA; 2015.

  • [14]

    Swen JJ, Nijenhuis M, van Rhenen M, de Boer-Veger NJ, Buunk AM, Houwink EJ. Pharmacogenetic information in clinical guidelines: the European perspective. Clin Pharmacol Ther 2018;103:795–801.Web of ScienceCrossrefPubMedGoogle Scholar

  • [15]

    Bank PC, Caudle KE, Swen JJ, Gammal RS, Whirl-Carrillo M, Klein TE, et al. Comparison of the guidelines of the clinical pharmacogenetics implementation consortium and the dutch pharmacogenetics working group. Clin Pharmacol Ther 2018;103:599–618.CrossrefWeb of ScienceGoogle Scholar

  • [16]

    Reis-Pardal J, Rodrigues A, Rodrigues E, Fernandez-Llimos F. Comparing cytochrome P450 pharmacogenetic information available on United States drug labels and European Union Summaries of Product Characteristics. Pharmacogenomics J 2017;17:488–93.PubMedCrossrefWeb of ScienceGoogle Scholar

  • [17]

    Shimazawa R, Ikeda M. Differences in pharmacogenomic biomarker information in package inserts from the United States, the United Kingdom and Japan. J Clin Pharm Ther 2013;38:468–75.Web of ScienceCrossrefPubMedGoogle Scholar

  • [18]

    U.S. National Library of Medicine. FDA Label: amitriptyline hydrochrolide. DailyMed; NIH NLM.Google Scholar

  • [19]

    Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclicantidepressants. Clin Pharmacol Ther 2013;93:402–8.PubMedCrossrefGoogle Scholar

  • [20]

    European Medicines Agency. Assessment report Referral under Article 30 of Directive 2001/83/EC. Committee for Medicinal Products for Human Use (CHMP); EMA/255467/2017. EMA; 2017.Google Scholar

  • [21]

    European Commission. Commission Implementing Decision of 8.5.2017 concerning, in the framework of Article 30 of Directive 2001/83/EC of the European Parliament and of the Council, the marketing authorisations for “Saroten and associated names,” medicinal products for human use which contain the active substance “amitriptyline;” Brussels.

  • [22]

    European Medicines Agency. List of nationally authorised medicinal products active substance: amitriptyline Procedure no.: PSUSA/00000168/201501.EMA/792231/2015.EMA; 2015.

About the article

Received: 2019-02-03

Accepted: 2019-02-11

Published Online: 2019-05-30


Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: Research funded by the ENDEAVOUR Scholarships scheme.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.


Citation Information: Drug Metabolism and Personalized Therapy, Volume 34, Issue 2, 20190005, ISSN (Online) 2363-8915, DOI: https://doi.org/10.1515/dmpt-2019-0005.

Export Citation

© 2019 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Comments (0)

Please log in or register to comment.
Log in